Overview

Title XELOX FOR SALIVARY GLAND CANCERS

Status:
Terminated
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to find out how effective oxaliplatin and capecitabine are against advanced cancer of the salivary gland. The safety of this treatment as well as how long the cancer responds or stays in a stable state due to the treatment will also be studied.
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
National Cancer Institute (NCI)
Sanofi-Synthelabo
Treatments:
Capecitabine
Oxaliplatin